AlphAIAlphAI — Financial news for AI agents
tradingview.com$RLAY

Jones Trading maintains Relay Therapeutics at Buy, raises price target to $31 from $20

Jones Trading reaffirmed its Buy rating for Relay Therapeutics and increased its price target to $31 from $20, citing a 66.7% upside from the Nov 6 close of $18.60.

Original reporting
tradingview.com
Published Nov 7, 2026, 12:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 12:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Jones Trading maintains Relay Therapeutics at Buy, raises price target to $31 from $20 — source image
Source · tradingview.com
Decision brief

The 30-second read

$RLAYBullishMed
01

Why it matters

The upgraded target could attract new capital and increase trading volume.

02

Market read

Analyst target raise provides a fresh catalyst for RLAY, offering a short-term trading opportunity.

03

What to watch

Potential dilution from upcoming financing rounds.

Relevance 6/10Novelty 5/10Timing: today

Background

Relay Therapeutics is a clinical-stage biotech developing precision medicines.

Company-level read

Ticker impact

$RLAYBullishHigh confidence
Context

Jones Trading raised its price target for Relay Therapeutics to $31 from $20, indicating a new bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The 55% target increase signals strong confidence in future performance, prompting buying interest.

Market effects

Sector

May lift sentiment in the biotech/clinical-stage sector.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Target may be overly optimistic given recent trial setbacks.

Key entities

  • Analyst
    Jones Trading

    Equity research firm that issued the rating upgrade.

Read at source← All news

Related articles

$RLAYHigh

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies t

SEC EDGAR 8-K
$RLAYMed

Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay

SEC EDGAR 8-K
$RLAYLowAI 8/10

Relay Therapeutics Shares Jump 18%

Relay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.

rttnews.com
$VIRHighAI 9/10

Vir’s Hepatitis Delta Drug Clears Phase 3 Trial, Shares Rise as $550M Licensing Deal Comes Into Focus - GeneOnline News

Vir Biotechnology's hepatitis delta drug combination met all Phase 3 trial endpoints, with 79% of patients achieving undetectable virus levels. Shares rose 11.8% to $13.65 on November 9. The company plans a mid-2027 FDA filing and has a €550M European licensing deal with Norgine. Vir has $901M in cash and expects funding to last into 2028. Competitors include Gilead and Mirum Pharmaceuticals.

geneonline.com